Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04863248
Title Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Docetaxel for Metastatic Non-Small Cell Lung Cancer (NSCLC) (PRESERVE 4)
Acronym PRESERVE 4
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors G1 Therapeutics, Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST